180 Life Sciences holds 82,186 ETH valued at $349 million

PALO ALTO - 180 Life Sciences Corp. (NASDAQ:ATNF), which does business as ETHZilla, announced Tuesday it has accumulated 82,186 Ether (ETH) at an average price of $3,806.71, now valued at approximately $349 million. The company, currently valued at $514.47 million by market capitalization, has shown significant price volatility according to InvestingPro data, with the stock recording a remarkable 147% gain over the past six months.

The company also holds approximately $238 million in USD cash equivalents, according to a press release statement. InvestingPro analysis indicates the company’s current ratio stands at 0.58, suggesting potential liquidity challenges despite its substantial crypto holdings.

"At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week," said McAndrew Rudisill, Executive Chairman of the company.

The most recently purchased ETH is expected to be held long-term and staked through Electric Capital’s proprietary Ethereum network strategies to generate yield. The company plans to rebrand as ETHZilla Corporation.

The company’s ETH holdings were reported as of August 11, 2025, while its outstanding shares total 154.032 million as of August 5, 2025.

180 Life Sciences, originally formed as a biotechnology company, has been evolving its business toward software-enabled gaming and entertainment. The company stated it continues to maintain and develop its gaming initiatives while also pursuing its ETH treasury strategy.

The firm aims to become "a benchmark for onchain treasury management among public companies" through its partnership with Electric Capital, pursuing what it describes as a differentiated yield generation program.

The company indicated it will provide future updates on its treasury and on-chain yield generation strategies through public releases and regulatory filings.

In other recent news, 180 Life Sciences Corp., which plans to rebrand as ETHZilla, has raised approximately $156 million through senior secured convertible notes due in 2028. This transaction follows the company’s earlier closing of a $425 million private placement aimed at funding its new Ethereum treasury strategy. The private placement was led by Electric Capital and Harbour Island, with participation from crypto-focused investors such as Borderless Capital and Polychain Capital. Additionally, 180 Life Sciences shareholders approved a significant increase in authorized common stock from 100 million to 1 billion shares. This amendment to the company’s certificate of incorporation was filed immediately after the annual meeting. Furthermore, the company’s Board of Directors has accelerated the vesting of equity awards for certain executives and non-executive directors. The accelerated awards include stock options and restricted stock grants for CEO Blair Jordan and Chief Accounting Officer Eric R. Van Lent. These recent developments highlight the company’s strategic shift and ongoing financial maneuvers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.